Izumiyama K[Author] - Search Results

Year	Number of Results
1987	1
1988	2
1989	1
1990	5
1991	1
2001	1
2002	5
2003	2
2004	7
2005	7
2006	3
2007	2
2008	4
2009	2
2010	1
2011	2
2012	7
2013	2
2014	3
2016	4
2017	1
2018	8
2019	4
2020	5
2021	7
2022	10
2023	11
2024	2

1

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.

Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M. Chiba M, et al. Among authors: izumiyama k. Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646. Blood. 2022. PMID: 35921533 Free PMC article.

2

Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.

Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H, Kobayashi M, Mori A, Morioka M, Kondo T. Ishio T, et al. Among authors: izumiyama k. Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12. Ann Hematol. 2023. PMID: 37041299 Free PMC article.

3

New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination.

Kobayashi M, Mori A, Oda Y, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Tanaka S, Morioka M, Kondo T. Kobayashi M, et al. Among authors: izumiyama k. Int J Hematol. 2023 Oct;118(4):477-482. doi: 10.1007/s12185-023-03618-7. Epub 2023 May 23. Int J Hematol. 2023. PMID: 37219678 Free PMC article.

4

Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.

Mori A, Onozawa M, Tsukamoto S, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: izumiyama k. Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14. Br J Haematol. 2022. PMID: 35226358 Free PMC article.

5

Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia.

Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: izumiyama k. Br J Haematol. 2023 Mar;200(6):717-721. doi: 10.1111/bjh.18578. Epub 2022 Nov 28. Br J Haematol. 2023. PMID: 36442510 Free PMC article.

6

Speech Recognition System Generates Highly Accurate Endoscopic Reports in Clinical Practice.

Takayama H, Takao T, Masumura R, Yamaguchi Y, Yonezawa R, Sakaguchi H, Morita Y, Toyonaga T, Izumiyama K, Kodama Y. Takayama H, et al. Among authors: izumiyama k. Intern Med. 2023 Jan 15;62(2):153-157. doi: 10.2169/internalmedicine.9592-22. Epub 2022 Jun 21. Intern Med. 2023. PMID: 35732450 Free PMC article.

7

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.

Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: izumiyama k. Cancer Med. 2023 Aug;12(16):16881-16888. doi: 10.1002/cam4.6314. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409608 Free PMC article.

8

Mori A, Onozawa M, Hidaka D, Yokoyama S, Miyajima T, Yokoyama E, Ogasawara R, Izumiyama K, Saito M, Fujisawa S, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Iwasaki H, Kobayashi H, Haseyama Y, Kurosawa M, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: izumiyama k. Int J Hematol. 2022 Feb;115(2):188-197. doi: 10.1007/s12185-021-03238-z. Epub 2021 Nov 5. Int J Hematol. 2022. PMID: 34739701

9

Hemodialysis Treatment Influences Postoperative Activities of Daily Living Improvement for Patients with Hip Fractures.

Tai K, Mitsunaga T, Kawasumi M, Kurata T, Sato Y, Izumiyama K. Tai K, et al. Among authors: izumiyama k. Prog Rehabil Med. 2023 Sep 21;8:20230031. doi: 10.2490/prm.20230031. eCollection 2023. Prog Rehabil Med. 2023. PMID: 37736257 Free PMC article.

10

[Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].

Kobayashi M, Yokoyama E, Izumiyama K, Mori A, Saito M, Morioka M, Kondo T. Kobayashi M, et al. Among authors: izumiyama k. Gan To Kagaku Ryoho. 2023 Sep;50(9):979-983. Gan To Kagaku Ryoho. 2023. PMID: 37800293 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year